Mirzotamab, an IgG1kappa antibody, targets CD276/B7-H3 and conjugates with Clezutoclax, a BCL-2 inhibitor, to create Mirzotamab clezutoclax. This antibody-drug conjugate (ADC), identified as ABBV-155, is currently under investigation in conjunction with taxa
CAS Number:
[2229859-11-2]
* VAT and and shipping costs not included. Errors and price changes excepted